HLA-A2

OSE Immunotherapeutics Provides Regulatory Update on Tedopi®, a Cancer Vaccine at a Late-Stage Clinical Development in Lung Cancer After Failure to Immunotherapies

Retrieved on: 
Wednesday, February 15, 2023
Research, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, HLA-A2, Immunotherapy, Safety, Maintenance, Patient, EMA, OSE, ISIN, European Medicines Agency, Failure, Survival rate, Mnemos EP, IO, ICI, US Foods, Quality of life, NSCLC, Pharmaceutical industry

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today provides a regulatory update on the clinical development plan of Tedopi®, an immunotherapy activating tumor specific T-cells, in phase 3 in monotherapy in advanced or metastatic non-small cell lung cancer (NSCLC) after checkpoint inhibitor failure (ICI).

Key Points: 
  • OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today provides a regulatory update on the clinical development plan of Tedopi®, an immunotherapy activating tumor specific T-cells, in phase 3 in monotherapy in advanced or metastatic non-small cell lung cancer (NSCLC) after checkpoint inhibitor failure (ICI).
  • The direct activation of tumor specific T-cells by Tedopi® differs from ICI releasing the break of immune response.
  • OSE Immunotherapeutics is committed to provide Tedopi® through cohort early access and nominative compassionate use programs across European countries to address patients’ needs alongside physicians’ engagement.
  • Under strict conditions, products in development can be made available to nominative patients who have a disease with no satisfactory authorized therapies and who cannot enter clinical trials ( https://www.ema.europa.eu/en/human-regulatory/research-development/compa... ).

PDC*line Pharma Presents First Immunological Results From Phase I/II Trial With PDC*lung01 at ESMO-IO 2022

Retrieved on: 
Friday, December 9, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Memory, Peptide, Melanoma, Blood bank, PBMC, HLA-A2, B cell, Antigen, Large-cell lung carcinoma, NK, Poster, MUC1, Patient, NY-ESO-1, PDC, Lung cancer, Hlas, GMP, Non-small-cell lung carcinoma, PD-1, RECIST, White blood cell, Safety, Cancer, Dendritic cell, ESMO, Human, RNA transfection, LOQ, Clinical trial, Growth, Bioreactor, MAGE, EFS, Pembrolizumab, Mutation, Pharmaceutical industry, Vaccine, NSCLC

The preliminary data was presented today at a poster display session at the ESMO Immuno-Oncology Congress 2022 (ESMO-IO) in Geneva (Switzerland).

Key Points: 
  • The preliminary data was presented today at a poster display session at the ESMO Immuno-Oncology Congress 2022 (ESMO-IO) in Geneva (Switzerland).
  • The objectives of the phase I/II trial (PDC-LUNG-101) are to assess the safety, tolerability, immunogenicity and preliminary clinical activity of the drug candidate PDC*lung01, associated or not with anti-PD-1 treatment in NSCLC patients.
  • It is administered weekly by a subcutaneous and intravenous route, in six consecutive doses.
  • Safety and clinical activity of the product were presented at ESMO 2022 in September 2022 in Paris (France).

Molecular Templates Provides Corporate Update and Outlines 2022 Milestones

Retrieved on: 
Tuesday, November 30, 2021
Patient, NSCLC, Pertuzumab, HER2, Trastuzumab, PD-L1, Technology, Company, Biology, Non-Hodgkin lymphoma, Multiple myeloma, MD, Cancer, Evercore, Tumor microenvironment, Șaeș, DLT, IND, ETB, NK, Myeloid-derived suppressor cell, Therapy, Breast cancer, SLAMF7, Melanoma, Infrared spectroscopy correlation table, Myocarditis, TIGIT, Cardiomyopathy, GLOBE, ETB (company), Antibody, CD38, Regulatory T cell, HLA-A2, PD-1, Immunotherapy, Doctor of Philosophy, CMV, MHC, Growth, NHL, CD8, Animal, Pharmaceutical industry, Vaccine, Gasoline

AUSTIN, Texas, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc.(Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), provided a corporate update and outlined expected 2022 milestones.

Key Points: 
  • MTEM to Present at Evercore ISI 4th Annual HealthCONx on December 2nd, 2021
    AUSTIN, Texas, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc.(Nasdaq: MTEM, Molecular Templates, or MTEM or the Company), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), provided a corporate update and outlined expected 2022 milestones.
  • 2021 was a year of growth for MTEM as we advanced our multiple pipeline programs, said Eric Poma, Ph.D., Chief Executive and Chief Scientific Officer of Molecular Templates.
  • MT-6402 was designed to directly destroy PD-L1+ tumor cells and alter the immunosuppressive tumor microenvironment through direct cell-kill of PD-L1+ immune cells.
  • No approved checkpoint agent has shown an ability to alter immune subset composition or induce cytokine changes in a PD-L1-targeted fashion, said Roger Waltzman, MD, Chief Medical Officer of Molecular Templates.